Curriculum Vitae

Personal information

Alberto Martire

Work experience

1. Employer: Istituto Superiore di Sanità
   - Start date: 032024
   - End date: present
   - Position: Senior Researcher
   - Activities:

   Current position: Senior Researcher, Senior Expert in Regulatory Affairs (pursuant to the EU Regulation No 536/2014), and member of the local Institutional Animal Care and Use Committee (IACUC, D.Lgs. 26/2014) as expert in Pharmacology.

   Areas of research interest: G-protein-coupled receptors' pharmacology and experimental models of neurological/neurodegenerative disorders.

   For the Italian National Competent Authorities (AIFA, ISS, Ministry of Health): non-clinical assessor of clinical trial authorization dossiers of medicinal products for human use (including biologics and ATMP), and reviewer of pharmacology, animal welfare, and 3Rs principles in experimental protocols involving laboratory animals.

   Assessment of new chemical products, monoclonal antibodies, biotechnology and ATMP dossiers (preclinical studies) for clinical trial authorization.

   Research: extracellular electrophysiology, molecular biology. Application: neuroscience, pharmacology of central nervous system, preclinical (in vitro, ex vivo, in vivo) studies for neurodegenerative/neuropsychiatric disorders, with a particular interest in the search for new therapeutic targets and biomarkers for Fragile X Syndrome.

   - Country: Italy
2. Employer: European Medicines Agency
   - Start date: 012023
   - End date: 012026
   - Position: Seconded National Expert
   - Activities:

   non-clinical consultancy and training to H-TA staff members and in the context of specific EMA projects (e.g., Innovation Task Force, PRIME).

   support to the development of the Neuroscience EMA/FDA cluster.

   support to procedure management of different kinds of marketing authorisations of human medicinal products, with active participation in the meetings of scientific committees (e.g., CHMP, PRAC, COMP, CAT).

   - Country: the Netherlands
3. Employer: Istituto Superiore di Sanità
   - Start date: 102013
   - End date: 022024
   - Position: Researcher
   - Activities:

   Assessment of new chemical products, monoclonal antibodies, biotechnology and ATMP dossiers (preclinical studies) for clinical trial authorization.

   Research: extracellular electrophysiology, molecular biology. Application: neuroscience, pharmacology of central nervous system, preclinical (in vitro, ex vivo, in vivo) studies for neurodegenerative/neuropsychiatric disorders, with a particular interest in the search for new therapeutic targets and biomarkers for Fragile X Syndrome.

   - Country: Italy
4. Employer: Istituto Superiore di Sanità
   - Start date: 102002
   - End date: 092013
   - Position: Research technician
   - Activities:

   Research: extracellular electrophysiology, molecular biology. Application: neuroscience, pharmacology of central nervous system, preclinical (in vitro, ex vivo, in vivo) studies for neurodegenerative/neuropsychiatric disorders.

   - Country: Italy

Education and training

1. Subject: University "La Sapienza"
   - Start date: 122001

- End date:
- Qualification: Degree in Biology
- Organisation:
- Country: Italy

2. Subject: University "La Sapienza"
   - Start date: 122009
   - End date:
   - Qualification: PhD in Pharmacology
   - Organisation:
   - Country: Italy

Additional information

Publications

1. Venturini G, Ferrante A, Carlo ND, Bertuccini L, Iosi F, Condello M, **Martire A**, Fratini F, Boussadia Z. Improvement of small extracellular vesicle isolation from mouse model blood. Extracell Vesicles Circ Nucl Acids. 2025 Dec 24;6(4):1034-1053. doi: 10.20517/evcna.2025.90. PMID: 41555857; PMCID: PMC12812443.
2. Mollinari C, Cardinale A, Lupacchini L, **Martire A**, Chiodi V, Martinelli A, Rinaldi AM, Fini M, Pazzaglia S, Domenici MR, Garaci E, Merlo D. The DNA repair protein DNA-PKcs modulates synaptic plasticity via PSD-95 phosphorylation and stability. EMBO Rep. 2024 Aug;25(8):3707-3737. doi: 10.1038/s44319-024-00198-3. Epub 2024 Jul 31. PMID: 39085642; PMCID: PMC11315936.
3. Di Rocco M, Galosi S, Follo FC, Lanza E, Folli V, **Martire A**, Leuzzi V, Martinelli S. Phenotypic Assessment of Pathogenic Variants in GNAO1 and Response to Caffeine in C. elegans Models of the Disease. Genes (Basel). 2023 Jan 26;14(2):319. doi: 10.3390/genes14020319. PMID: 36833246; PMCID: PMC9957173.
4. Borreca A, De Luca M, Ferrante A, Boussadia Z, Pignataro A, **Martire A**, Ammassari-Teule M. Fmr1-KO mice failure to detect object novelty associates with a post-test decrease of structural and synaptic plasticity upstream of the hippocampus. Sci Rep. 2023 Jan 14;13(1):755. doi: 10.1038/s41598-023-27991-9. PMID: 36641518; PMCID: PMC9840621.
5. Boussadia Z, Chiodi V, Pazienti A, **Martire A**. A major role for adenosine A2A receptor in the interaction between astrocytes and myelinated neurons: possible implications for the therapy of neurodegenerative disorders. Purinergic Signal. 2022 Jan 23. doi: 10.1007/s11302-021-09835-1. Epub ahead of print. PMID: 35066787.
6. Pisa E, **Martire A**, Chiodi V, Traversa A, Caputo V, Hauser J, Macrì S. Exposure to 3'Sialyllactose-Poor Milk during Lactation Impairs Cognitive Capabilities in Adulthood. Nutrients. 2021 Nov 23;13(12):4191. doi: 10.3390/nu13124191. PMID: 34959743; PMCID: PMC8707534.
7. Di Rocco M, Galosi S, Lanza E, Tosato F, Caprini D, Folli V, Friedman J, Bocchinfuso G, **Martire A**, Di Schiavi E, Leuzzi V, Martinelli S. Caenorhabditis elegans provides an efficient drug screening platform for GNAO1-related disorders and highlights the potential role of caffeine in controlling dyskinesia. Hum Mol Genet. 2021 Oct 8:ddab296. doi: 10.1093/hmg/ddab296. Epub ahead of print. PMID: 34622282.
8. Bernardo A, De Nuccio C, Visentin S, **Martire A**, Minghetti L, Popoli P, Ferrante A. Myelin Defects in Niemann-Pick Type C Disease: Mechanisms and Possible Therapeutic Perspectives. Int J Mol Sci. 2021 Aug 17;22(16):8858. doi: 10.3390/ijms22168858. PMID: 34445564; PMCID: PMC8396228.
9. Hauser J, Pisa E, Arias Vásquez A, Tomasi F, Traversa A, Chiodi V, Martin FP, Sprenger N, Lukjancenko O, Zollinger A, Metairon S, Schneider N, Steiner P, **Martire A**, Caputo V, Macrì S. Sialylated human milk oligosaccharides program cognitive development through a non-genomic transmission mode. Mol Psychiatry. 2021 Mar 4. doi: 10.1038/s41380-021-01054-9. PMID: 33664475.
10. **Martire A**, Pepponi R, Liguori F, Volonté C, Popoli P. P2X7 Receptor Agonist 2'(3')-O-(4-Benzoylbenzoyl)ATP Differently Modulates Cell Viability and Corticostriatal Synaptic Transmission in Experimental Models of Huntington's Disease. Front Pharmacol. 2021 Feb 19; 11:633861. doi: 10.3389/fphar.2020.633861. PMID: 33679392; PMCID: PMC7933594.
11. Ferrante A, Boussadia Z, Borreca A, Mallozzi C, Pedini G, Pacini L, Pezzola A, Armida M, Vincenzi F, Varani K, Bagni C, Popoli P, **Martire A**. Adenosine A2A receptor inhibition reduces synaptic and cognitive hippocampal alterations in Fmr1 KO mice. Transl Psychiatry. 2021 Feb 5;11(1):112. doi: 10.1038/s41398-021-01238-5. PMID: 33547274; PMCID: PMC7864914**.**
12. Ferrante A, Visentin S, De Nuccio C, **Martire A**, Popoli P. Adenosine and Adenosine A2A Receptors as Targets for the Treatment of Niemann Pick Type C Disease. Journal of Caffeine and Adenosine Research. Sep 2019. 98-103. http://doi.org/10.1089/caff.2019.0014.
13. De Nuccio C, Bernardo A, Ferrante A, Pepponi R, **Martire A**, Falchi M, Visentin S, Popoli P, Minghetti L. Adenosine A2A receptor stimulation restores cell functions and differentiation in Niemann-Pick type C-like oligodendrocytes. Sci Rep. 2019 Jul 5;9(1):9782. doi: 10.1038/s41598-019-46268-8. PMID: 31278313; PMCID: PMC6611770.
14. Domenici MR, Ferrante A, **Martire A**, Chiodi V, Pepponi R, Tebano MT, Popoli P. Adenosine A2A receptor as potential therapeutic target in neuropsychiatric disorders. Pharmacol Res. 2019 Sep; 147:104338. doi: 10.1016/j.phrs.2019.104338. Epub 2019 Jul 2. PMID: 31276772.
15. **Martire A**, Lambertucci C, Pepponi R, Ferrante A, Benati N, Buccioni M, Dal Ben D, Marucci G, Klotz KN, Volpini R, Popoli P. Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia. J Neurochem. 2019 Apr;149(2):211-230. doi: 10.1111/jnc.14660. Epub 2019 Feb 11. PMID: 30614535.
16. Ferrante A, Pezzola A, Matteucci A, Di Biase A, Attorri L, Armida M, **Martire A**, Chern Y, Popoli P. The adenosine A2A receptor agonist T1-11 ameliorates neurovisceral symptoms and extends the lifespan of a mouse model of Niemann-Pick type C disease. Neurobiol Dis. 2018 Feb; 110:1-11. doi: 10.1016/j.nbd.2017.10.013. Epub 2017 Oct 25. PMID: 29079454.
17. Ferrante A, Tebano MT, **Martire A**, Domenici MR, Popoli P. Book Chapter: Neuronal vs Glial Cell Contribution to Adenosine A2A Receptor-Induced Neurodegeneration. In David Blum and Luísa V.Lopes, editors: Blum - Adenosine Receptors in Neurodegenerative Diseases, Oxford: Academic Press , 2017 , pp. 131 - 150.
18. Cilli P, Ventura I, Minoprio A, Meccia E, **Martire A**, Wilson SH, Bignami M, Mazzei F. Oxidized dNTPs and the OGG1 and MUTYH DNA glycosylases combine to induce CAG/CTG repeat instability. Nucleic Acids Res. 2016 Jun 20;44(11):5190-203. doi: 10.1093/nar/gkw170. Epub 2016 Mar 14. PMID: 26980281; PMCID: PMC4914090.
19. Ferrante A, De Nuccio C, Pepponi R, Visentin S, **Martire A**, Bernardo A, Minghetti L, Popoli P. Stimulation of adenosine A2A receptors reduces intracellular cholesterol accumulation and rescues mitochondrial abnormalities in human neural cell models of Niemann-Pick C1. Neuropharmacology. 2016 Apr; 103:155-62. doi: 10.1016/j.neuropharm.2015.11.022. Epub 2015 Nov 26. PMID: 26631535.
20. Popoli P, Domenici MR, **Martire A**, Tebano MT. Book Chapter: Functional Interactions of Adenosine Receptors and their Possible Implications in Central Nervous System Diseases. Chapter 13, pp. 265-294, in "Adenosine Signaling Mechanisms: Pharmacology, Functions and Therapeutic Aspects". 2015. Vickram Ramkumar and Roberto Paes de Carvalho Eds. Nova Science Publishers.
21. De Felice A, Confaloni A, Crestini A, De Simone R, Malchiodi-Albedi F, **Martire A**, Matteucci A, Minghetti L, Popoli P, Venerosi A, Calamandrei G. Book Chapter: Branched Chain Amino Acids in Experimental Models of Amyotrophic Lateral Sclerosis, in "Branched Chain Amino Acids in Clinical Nutrition". 2015. Springer New York.
22. Ferrante A, **Martire A**, Pepponi R, Varani K, Vincenzi F, Ferraro L, Beggiato S, Tebano MT, Popoli P. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease. Neurobiol Dis. 2014 Nov; 71:193-204. doi: 10.1016/j.nbd.2014.08.013. Epub 2014 Aug 15. PMID: 25132555.

23. De Luca G, Ventura I, Sanghez V, Russo MT, Ajmone-Cat MA, Cacci E, **Martire A**, Popoli P, Falcone G, Michelini F, Crescenzi M, Degan P, Minghetti L, Bignami M, Calamandrei G. Prolonged lifespan with enhanced exploratory behavior in mice overexpressing the oxidized nucleoside triphosphatase hMTH1. Aging Cell. 2013 Aug;12(4):695-705. doi: 10.1111/acel.12094. Epub 2013 May 30. PMID: 23648059.
24. **Martire A**, Pepponi R, Domenici MR, Ferrante A, Chiodi V, Popoli P. BDNF prevents NMDA-induced toxicity in models of Huntington's disease: the effects are genotype specific and adenosine A2A receptor is involved. J Neurochem. 2013 Apr;125(2):225-35. doi: 10.1111/jnc.12177. Epub 2013 Feb 27. PMID: 23363456.
25. Blum D, **Martire A**, Burnouf S, Sablonnière B, Krystkowiak P, Ledent C, Lopes LV, Popoli P. Book Chapter: Adenosine receptors in Huntington's disease. Chapter 20 in "Adenosine: a Key Link between Metabolism and CNS Activity". 2013. Masino & Boison Eds. Springer.
26. Scattoni ML, **Martire A**, Cartocci G, Ferrante A, Ricceri L. Reduced social interaction, behavioural flexibility and BDNF signalling in the BTBR T+ tf/J strain, a mouse model of autism. Behav Brain Res. 2013 Aug 15; 251:35-40. doi: 10.1016/j.bbr.2012.12.028. Epub 2012 Dec 25. PMID: 23270976.
27. Burnouf S, **Martire A**, Derisbourg M, Laurent C, Belarbi K, Leboucher A, Fernandez-Gomez FJ, Troquier L, Eddarkaoui S, Grosjean ME, Demeyer D, Muhr-Tailleux A, Buisson A, Sergeant N, Hamdane M, Humez S, Popoli P, Buée L, Blum D. NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a Tau transgenic model. Aging Cell. 2013 Feb;12(1):11-23. doi: 10.1111/acel.12018. Epub 2012 Nov 23. PMID: 23082852.
28. Tebano MT, **Martire A**, Popoli P. Adenosine A(2A)-cannabinoid CB(1) receptor interaction: an integrative mechanism in striatal glutamatergic neurotransmission. Brain Res. 2012 Oct 2;1476:108-18. doi: 10.1016/j.brainres.2012.04.051. Epub 2012 May 4. PMID: 22565012.
29. Chiodi V, Uchigashima M, Beggiato S, Ferrante A, Armida M, **Martire A**, Potenza RL, Ferraro L, Tanganelli S, Watanabe M, Domenici MR, Popoli P. Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease. Neurobiol Dis. 2012 Mar;45(3):983-91. doi: 10.1016/j.nbd.2011.12.017. Epub 2011 Dec 23. PMID: 22207189.
30. Venerosi A, **Martire A**, Rungi A, Pieri M, Ferrante A, Zona C, Popoli P, Calamandrei G. Complex behavioral and synaptic effects of dietary branched chain amino acids in a mouse model of amyotrophic lateral sclerosis. Mol Nutr Food Res. 2011 Apr; 55(4):541-52. doi: 10.1002/mnfr.201000296. Epub 2011 Jan 5. PMID: 21462321.
31. **Martire A**, Tebano MT, Chiodi V, Ferreira SG, Cunha RA, Köfalvi A, Popoli P. Pre-synaptic adenosine A2A receptors control cannabinoid CB1 receptor-mediated inhibition of striatal glutamatergic neurotransmission. J Neurochem. 2011 Jan; 116(2):273-80. doi: 10.1111/j.1471-4159.2010.07101.x. Epub 2010 Dec 2. PMID: 21062287.
32. Tebano MT, **Martire A**, Chiodi V, Ferrante A, Popoli P. Role of adenosine A(2A) receptors in modulating synaptic functions and brain levels of BDNF: a possible key mechanism in the pathophysiology of Huntington's disease. ScientificWorldJournal. 2010 Sep 1; 10:1768-82. doi: 10.1100/tsw.2010.164. PMID: 20842321; PMCID: PMC5763899.
33. Ferrante A, **Martire A**, Armida M, Chiodi V, Pézzola A, Potenza RL, Domenici MR, Popoli P. Influence of CGS 21680, a selective adenosine A(2A) receptor agonist, on NMDA receptor function and expression in the brain of Huntington's disease mice. Brain Res. 2010 Apr 6; 1323:184-91. doi: 10.1016/j.brainres.2010.01.080. Epub 2010 Feb 4. PMID: 20138162.
34. **Martire A**, Ferrante A, Potenza RL, Armida M, Ferretti R, Pézzola A, Domenici MR, Popoli P. Remodeling of striatal NMDA receptors by chronic A(2A) receptor blockade in Huntington's disease mice. Neurobiol Dis. 2010 Jan;37(1):99-105. doi: 10.1016/j.nbd.2009.09.012. Epub 2009 Oct 3. PMID: 19804830.
35. Tebano MT, **Martire A**, Chiodi V, Pepponi R, Ferrante A, Domenici MR, Frank C, Chen JF, Ledent C, Popoli P. Adenosine A2A receptors enable the synaptic effects of cannabinoid CB1 receptors in the rodent striatum. J Neurochem. 2009 Sep; 110(6):1921-30. doi: 10.1111/j.1471-4159.2009.06282.x. Epub 2009 Jul 17. PMID: 19627447.
36. Pepponi R, Ferrante A, Ferretti R, **Martire A**, Popoli P. Region-specific neuroprotective effect of ZM 241385 towards glutamate uptake inhibition in cultured neurons. Eur J Pharmacol. 2009 Sep 1;617(1-3):28-32. doi: 10.1016/j.ejphar.2009.07.016. Epub 2009 Jul 18. PMID: 19619523.
37. Tebano MT, **Martire A**, Pepponi R, Domenici MR, Popoli P. Is the functional interaction between adenosine A(2A) receptors and metabotropic glutamate 5 receptors a general mechanism in the brain? Differences and similarities between the striatum and the hippocampus. Purinergic Signal. 2006 Nov; 2(4):619-25. doi: 10.1007/s11302-006-9026-y. Epub 2006 Sep 28. PMID: 18404464; PMCID: PMC2096652.
38. Potenza RL, Tebano MT, **Martire A**, Domenici MR, Pepponi R, Armida M, Pèzzola A, Minghetti L, Popoli P. Adenosine A(2A) receptors modulate BDNF both in normal conditions and in experimental models of Huntington's disease. Purinergic Signal. 2007 Sep; 3(4):333-8. doi: 10.1007/s11302-007-9066-y. Epub 2007 Sep 15. PMID: 18404446; PMCID: PMC2072926.
39. Tebano MT, **Martire A**, Potenza RL, Grò C, Pepponi R, Armida M, Domenici MR, Schwarzschild MA, Chen JF, Popoli P. Adenosine A(2A) receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus. J Neurochem. 2008 Jan; 104(1):279-86. doi: 10.1111/j.1471-4159.2007.05046.x. Epub 2007 Nov 14. PMID: 18005343.
40. Popoli P, Pepponi R, **Martire A**, Armida M, Pèzzola A, Galluzzo M, Domenici MR, Potenza RL, Tebano MT, Mollinari C, Merlo D, Garaci E. Neuroprotective effects of thymosin beta4 in experimental models of excitotoxicity. Ann N Y Acad Sci. 2007 Sep; 1112:219-24. doi: 10.1196/annals.1415.033. PMID: 17947590.
41. Domenici MR, Scattoni ML, **Martire A**, Lastoria G, Potenza RL, Borioni A, Venerosi A, Calamandrei G, Popoli P. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice. Neurobiol Dis. 2007 Nov;28(2):197-205. doi: 10.1016/j.nbd.2007.07.009. Epub 2007 Jul 24. PMID: 17720507.
42. Bisogno T, **Martire A**, Petrosino S, Popoli P, Di Marzo V. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease. Neurochem Int. 2008 Jan;52(1-2):307-13. doi: 10.1016/j.neuint.2007.06.031. Epub 2007 Jul 4. PMID: 17664017.
43. **Martire A**, Calamandrei G, Felici F, Scattoni ML, Lastoria G, Domenici MR, Tebano MT, Popoli P. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice. Neurosci Lett. 2007 Apr 24;417(1):78-83. doi: 10.1016/j.neulet.2007.02.034. Epub 2007 Feb 14. PMID: 17331645.
44. Popoli P, Blum D, **Martire A**, Ledent C, Ceruti S, Abbracchio MP. Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease. Prog Neurobiol. 2007 Apr;81(5-6):331-48. doi: 10.1016/j.pneurobio.2006.12.005. Epub 2007 Jan 9. PMID: 17303312.
45. Mallozzi C, **Martire A**, Domenici MR, Metere A, Popoli P, Di Stasi AM. L-NAME reverses quinolinic acid-induced toxicity in rat corticostriatal slices: Involvement of src family kinases. J Neurosci Res. 2007 Sep;85(12):2770-7. doi: 10.1002/jnr.21178. PMID: 17265464.
46. Pintor A, Tebano MT, **Martire A**, Grieco R, Galluzzo M, Scattoni ML, Pèzzola A, Coccurello R, Felici F, Cuomo V, Piomelli D, Calamandrei G, Popoli P. The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacology. 2006 Oct;51(5):1004-12. doi: 10.1016/j.neuropharm.2006.06.013. Epub 2006 Aug 8. PMID: 16895732.
47. Tebano MT, **Martire A**, Rebola N, Pepponi R, Domenici MR, Grò MC, Schwarzschild MA, Chen JF, Cunha RA, Popoli P. Adenosine A2A receptors and metabotropic glutamate 5 receptors are co-localized and functionally interact in the hippocampus: a possible key mechanism in the modulation of N-methyl-D-aspartate effects. J Neurochem. 2005 Nov;95(4):1188-200. doi: 10.1111/j.1471-4159.2005.03455.x. PMID: 16271052.
48. Domenici MR, Potenza RL, **Martire A**, Coccurello R, Pèzzola A, Reggio R, Tebano MT, Popoli P. Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats: possible relevance to the effects of mGlu5R blockade in

Parkinson's disease. J Neurosci Res. 2005 Jun 1;80(5):646-54. doi: 10.1002/jnr.20489. PMID: 15880742.
49. Domenici MR, Pepponi R, **Martire A**, Tebano MT, Potenza RL, Popoli P. Permissive role of adenosine A2A receptors on metabotropic glutamate receptor 5 (mGluR5)-mediated effects in the striatum. J Neurochem. 2004 Sep;90(5):1276-9. doi: 10.1111/j.1471-4159.2004.02607.x. PMID: 15312183.
50. Tebano MT, Pintor A, Frank C, Domenici MR, **Martire A**, Pepponi R, Potenza RL, Grieco R, Popoli P. Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum. J Neurosci Res. 2004 Jul 1;77(1):100-7. doi: 10.1002/jnr.20138. PMID: 15197743.
51. Popoli P, Pintor A, Tebano MT, Frank C, Pepponi R, Nazzicone V, Grieco R, Pèzzola A, Reggio R, Minghetti L, De Berardinis MA, **Martire A**, Potenza RL, Domenici MR, Massotti M. Neuroprotective effects of the mGlu5R antagonist MPEP towards quinolinic acid-induced striatal toxicity: involvement of pre- and post-synaptic mechanisms and lack of direct NMDA blocking activity. J Neurochem. 2004 Jun;89(6):1479-89. doi: 10.1111/j.1471-4159.2004.02448.x. PMID: 15189351.
52. Sciamanna I, Barberi L, **Martire A**, Pittoggi C, Beraldi R, Giordano R, Magnano AR, Hogdson C, Spadafora C. Sperm endogenous reverse transcriptase as mediator of new genetic information. Biochem Biophys Res Commun. 2003 Dec 26;312(4):1039-46. doi: 10.1016/j.bbrc.2003.11.024. PMID: 14651976.

Projects

Since January 2014: principal investigator of the following project: GR-2011-02348150 "Adenosine A2A receptors as a possible therapeutic target in Niemann-Pick type C disease" (Young Researchers Funding of Euro 342,000.00 from the Ministry of Health for the years 2014-2015-2016).

Since October 2018: principal investigator of the following project: "Characterization of Adenosine Receptors in a Mouse Model of Fragile X Syndrome" (contribution of 90,000.00 USD from the FRAXA Research Foundation for 2018-2019).

Since October 2021: collaborator in the following project: "Characterization of microglia transcriptional profile in fmr1ko mice model"; FRAXA Research Foundation; 2021-2023.

Since July 2021: principal investigator of the following project: "Exosomes as a source of Therapeutic Biomarkers in Experimental Models of Fragile X Syndrome"; ISS intramural funding; 2020-2022.

Since October 2022: principal investigator of the following project: "Exosomes as a source of Therapeutic Biomarkers in Experimental Models of Fragile X Syndrome " (contribution of 100,000.00 USD from the FRAXA Research Foundation for 2023-2024).

Memberships

Other Relevant Information